Escape for Smoking Behaviors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Smoking Behaviors+5 More
Escape - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the ESCAPE program to see if it can help women with HIV quit smoking and improve their lung health.

Eligible Conditions
  • Smoking Behaviors
  • Smoking
  • Tobacco
  • Lung
  • Smoking, Cessation

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: 6 months

1 month
Percentage of the group perceive the film as just right in length
3 months
Completion rate
Narrative Engagement Scale scores
Percentage of the group indicate that the film would have value to others
6 months
7-day point prevalence smoking cessation rate
Malignant Neoplasms
Polygenic risk score (PRS)
Qualitative interviews
number of cigarettes smoked/day

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard Care
1 of 2
Escape
1 of 2
Experimental Treatment

153 Total Participants · 2 Treatment Groups

Primary Treatment: Escape · No Placebo Group · N/A

Standard Care
Other
Experimental Group · 1 Intervention: Standard Care · Intervention Types: Other
Escape
Other
Experimental Group · 1 Intervention: Escape · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,012 Previous Clinical Trials
393,206 Total Patients Enrolled
American Association for Cancer ResearchOTHER
8 Previous Clinical Trials
741 Total Patients Enrolled
Mary E. Cooley, PhDPrincipal Investigator - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
1 Previous Clinical Trials
179 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a 30 pack year smoking history.
You smoke ≥ 5 cigarettes/day.
You have a primary care provider.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 24th, 2021

Last Reviewed: October 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.